Bladder Neoplasms

21 registered clinical trials studyying Bladder Neoplasms — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder NCT05072600	Peking University First Hospital	Phase 2
Terminated	CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physicia NCT02900248	CureOne	—
Completed	Image-Guided Tumorboost of Bladder Cancer NCT00963404	University of Aarhus	Phase 1 / Phase 2
Completed	Bladder Cancer Patient-Reported Outcomes NCT01090388	Baylor College of Medicine	—
Completed	Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ NCT00462488	Sesen Bio, Inc.	Phase 2
Completed	Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder C NCT00406068	Bioniche Life Sciences Inc.	Phase 2 / Phase 3
Completed	A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Stu NCT00536588	Merck Sharp & Dohme LLC	Phase 1
Completed	Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer NCT00393809	Hebrew University of Jerusalem	Phase 1 / Phase 2
Completed	Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional NCT00315237	Pierre Fabre Medicament	Phase 3
Completed	Phase II Trial of EOquin in High-risk Superficial Bladder Cancer NCT00141531	Spectrum Pharmaceuticals, Inc	Phase 2
Unknown	Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure NCT00109655	Cell Genesys	Phase 1
Completed	Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium NCT00101608	Bristol-Myers Squibb	Phase 2
Completed	Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide NCT00188695	University Health Network, Toronto	Phase 1 / Phase 2
Terminated	Instillation of Gemcitabine in Patients With Superficial Bladder Cancer NCT00191477	Eli Lilly and Company	Phase 3
Completed	TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Uroth NCT00077688	Achieve Life Sciences	Phase 2
Completed	Intravesical Chemotherapy Treatment of Superficial Bladder Cancer NCT00491114	Eli Lilly and Company	Phase 2
Recruiting	Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer NCT00872495	Lahey Clinic	—
Terminated	Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies NCT00050687	Titan Pharmaceuticals	Phase 1 / Phase 2
Completed	Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder NCT00343356	LanZhou University	Phase 2
Completed	A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder NCT00001381	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Molecular Analysis Of Bladder Cancer NCT00871754	Lahey Clinic	—